Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin

NCT00221624 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT00221624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00221624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
April 30, 2004
Enrollment
131 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcv infection, hepatitis c, chronic